- The key vendors in the global chronic lymphocytic leukemia therapeutics market 2015-2019 are F. Hoffmann-La Roche Ltd., Novartis AG and Teva Pharmaceutical Industries Ltd.
London, 03 August 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global chronic lymphocytic leukemia therapeutics market 2015-2019. Vendors are increasingly forming strategic alliances to increase their market shares. Co-development agreements allow the sharing of regulatory and developmental experiences gained by either company to support pipeline candidates. The global chronic lymphocytic leukemia therapeutics market is growing at a fast pace and is expected to post a CAGR of 18.52% during the forecast period of 2014-2019.
Recently US FDA approval has been given to a number of drugs for the treatment of chronic lymphocytic leukemia. These drugs are expected to penetrate the market within the forecast period. The drugs are currently in the introduction phase and growth in their sales will be observed during the forecast period. The market has significant unmet needs and the approval of these drugs by the US FDA has facilitated the uptake of these drugs by patients.
“Growing awareness about chronic lymphocytic leukemia increases the sales and use of the drugs. Some of the organizations involved in spreading awareness about the disease are Cancer Research UK, the Canadian Cancer Society, the CLL Global Research Foundation, the Lymphoma Research Foundation, the Leukemia Foundation, the Leukemia Research Foundation, and the Leukemia and Lymphoma Society,” says Faisal Ghaus, Vice President of Technavio Research.
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
